PLANO, Texas, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the third quarter ended Sept. 26, 2025, on Thursday, Oct. 23, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the third quarter on Oct. 23 prior to the conference ca ...

Core Viewpoint - WORK Medical Technology Group LTD has entered into a strategic cooperation agreement with the Hong Kong Web3.0 Standardization Association to promote innovation in the Real-world Asset (RWA) sector through resource sharing and complementary strengths [1][4]. Group 1: Strategic Cooperation Agreement - The agreement focuses on collaboration in blockchain solutions, including asset tokenization, equity investment, and RWA technology development [4][5]. - WORK Medical will leverage its capital resources and expertise in medical device manufacturing alongside the Association's resources to advance asset tokenization [4]. - The partnership aims to integrate industrial and financial resources for co-investments to accelerate RWA market expansion [4]. Group 2: Association's Role and Objectives - The Hong Kong Web3.0 Standardization Association is dedicated to supporting the growth of Hong Kong's Web3.0 ecosystem through standardization and research [6]. - The Association's initiatives include promoting technological advancement, establishing standards, and enhancing public awareness of Web3.0 [6]. - The Association launched an RWA registration platform in August 2025 to further its mission [6]. Group 3: Company Profile - WORK Medical develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 regions in China and over 30 countries worldwide [8]. - The company has received quality-related manufacturing designations and has registered 17 products with the U.S. FDA for market entry in the U.S. [8].

Swedish medical technology company Mölnlycke Health Care has started construction on the expansion of its $135m wound care manufacturing facility in Brunswick, Maine, US. The facility expansion aims to enhance the company's production capacity in the US. It will incorporate renewable energy solutions, such as wind and solar power, to meet Mölnlycke’s sustainability targets. Additionally, the plant will feature advanced machinery from suppliers in the US. Over the coming five years, the expansion is exp ...

Group 1 - Helius Medical Technologies has raised $500 million through a private placement in public equity (PIPE) to create a Solana treasury, indicating a shift among Nasdaq-traded companies towards accumulating SOL [1][2] - The PIPE offering was led by venture capital firms Pantera Capital and Summer Capital, with participation from several other notable investors, and is expected to close soon [2] - The announcement follows a trend of companies establishing Solana treasuries to capitalize on the rising digital asset markets, contributing to a rally in crypto prices, with Solana recently trading at $233, up nearly 60% over the past three months [3] Group 2 - Helius shares experienced a significant increase, closing at $18.27, which is a 141% rise in trading, recovering some losses from the past year [4] - The PIPE was described as "oversubscribed," with participants purchasing common stock at $6.81 and stapled warrants with an exercise price of $10.13, which can be exercised for three years [5] - The CEO of Helius humorously clarified on social media that his company is not involved in the treasury, highlighting the confusion surrounding the announcement [6][7]

Core Insights - The Dominican Republic is becoming a significant player in the medical device manufacturing sector, attracting global medtech firms for nearshoring opportunities [1] - The country is seen as a solution for supply chain resilience and cost efficiency in the post-pandemic environment [1] Industry Trends - The capsule endoscopy market is expanding, with potential to surpass traditional endoscopy in the near future, although there are challenges to overcome [2] - ESG compliance is increasingly influencing partnerships within the medical device manufacturing industry, reshaping how companies collaborate [2]

Core Insights - Nordson Corporation (NDSN) has divested its design and development contract manufacturing business units to Quasar Medical, with financial terms undisclosed [1][8] - Following the announcement, Nordson's shares fell by 1.1%, closing at $222.70 [1] Business Operations - Nordson Medical's contract manufacturing businesses, located in Galway, Ireland, and Tecate, Mexico, provide comprehensive solutions for complex interventional devices in the medical industry [2] - The Galway facility will now serve as Quasar Medical's innovation center for advanced medical device manufacturing processes, while the Tecate facility will function as a manufacturing hub for packaging, coating, molding, and automated processes [3] Strategic Alignment - This divestment aligns with Nordson's business transformation strategy aimed at unlocking shareholder value by focusing on core operations and optimizing its Medical and Fluid Solutions portfolio [4] - The divestiture allows Nordson to strengthen its medical component offerings, which include cannulas, catheters, medical balloons, and fluid management solutions [4] Market Performance - Nordson has a market capitalization of $12.5 billion and currently holds a Zacks Rank 2 (Buy) [5] - The company is experiencing strong momentum in its Advanced Technology Solutions segment, driven by customer demand in nonwovens, packaging, consumer non-durable, and optical sensors product lines [5] - Over the past month, Nordson's shares have increased by 4.8%, outperforming the industry growth of 2.4% [6] - The Zacks Consensus Estimate for Nordson's fiscal 2025 earnings is projected at $10.07 per share, reflecting a 0.4% increase from the previous estimate [6]

Core Insights - Quasar Medical has completed the acquisition of Nordson Corporation's design & development contract manufacturing businesses, enhancing its global CDMO platform and capabilities for medical device OEMs and innovators [1][3]. Company Expansion - The acquisition marks Quasar's evolution into a fully integrated CDMO, providing concept-to-commercialization solutions worldwide and expanding its workforce by nearly 200 employees [2][5]. - The addition of two FDA-registered, ISO 13485-certified facilities in Galway, Ireland, and Tecate, Mexico, strengthens Quasar's global presence and improves customer proximity [3][4]. Operational Enhancements - The Galway facility will serve as an innovation hub for design & development, focusing on extrusions, braiding, balloons, and complex catheters, while Tecate will provide cost-effective, high-volume manufacturing capabilities [3][5]. - The acquisition enhances Quasar's cleanroom footprint and technical expertise in various medical device technologies, leading to faster development and improved quality control [5][7]. Strategic Positioning - Quasar aims to position itself as a strategic partner to customers, offering a differentiated platform that combines upstream innovation and downstream scalability [4][6]. - The company will collaborate closely with Nordson to ensure a seamless transition for employees, customers, and suppliers [6].

BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. About Cirtec Medical Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing in active implant systems, interventional devices, ...

Summary of UFP Technologies Conference Call Company Overview - UFP Technologies (Ticker: UFPT) is based in Newburyport, Massachusetts with a market cap close to $2 billion and revenue of approximately $600 million, of which about $550 million is from medical revenue [6][34] - The company operates 22 locations globally with around 4,000 employees and has six development labs that are crucial for its contract development manufacturing organization (CDMO) model [7][34] Core Business and Innovations - UFP Technologies specializes in developing innovative medical devices that improve patient outcomes, working with 26 of the top 30 medical device companies globally [6][8] - The company focuses on high-margin product development, engaging clients early in the development process to create custom manufacturing processes [9][34] - Key technologies include negative pressure wound therapy, robotic surgical drapes, and infection prevention devices [10][15][18] Market Opportunity - The medtech market is valued at $500 billion and is growing at 6.3%, while the outsourcing market is close to $100 billion and growing at 10-11% [20][29] - UFP Technologies targets segments with high risk of failure and low average selling prices, particularly in single-use, plastic-based products [21][36] - The company has identified over 20 defined segments in the medical space, servicing eight with revenues of $15 million or more [22][36] Growth Strategy - UFP Technologies employs a two-pronged growth strategy focusing on organic growth in faster-growing segments and strategic acquisitions [25][27] - The management team has a history of successful acquisitions, completing nine deals in the medtech space since 2021 [27][34] - Financial targets include revenue growth of 12-18% and gross margins of 28-31% [34][35] Competitive Landscape - The market is highly fragmented with approximately 900 private equity-backed CDMOs, making it challenging for new entrants due to regulatory barriers [38] - UFP Technologies has established strong relationships with major clients like Intuitive Surgical and Stryker, which are critical for its growth [39][40] Financial Performance - Medical revenue has grown from $132 million to $540 million, representing a compound annual growth rate (CAGR) of approximately 40% [28][34] - The company has experienced some headwinds related to onboarding new employees but remains confident in meeting its financial targets [51][53] Key Differentiators - UFP Technologies boasts a team of over 100 engineers who provide technical value and foster strong supplier relationships, giving the company a competitive edge [32][34] - The company emphasizes customer-centric M&A, focusing on adding value to clients and enhancing capabilities [28][36] Conclusion - UFP Technologies is positioned in a growing market with significant opportunities for outsourcing and innovation, backed by a proven management team and a strong growth strategy [36][37]

Core Viewpoint - Integer Holdings Corporation is actively participating in the 2025 Wells Fargo Healthcare Conference, indicating its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Company Overview - Integer Holdings Corporation (NYSE: ITGR) is a leading medical device contract development and manufacturing organization (CDMO) globally, focusing on cardiac rhythm management, neuromodulation, and cardio and vascular markets [3]. - The company serves as a strategic partner for medical device companies and OEMs, aiming to enhance patient lives through innovative and high-quality products [3]. - Integer's notable brands include Greatbatch Medical and Lake Region Medical, reflecting its strong market presence [3]. Event Participation - The executive leadership team of Integer will participate in a fireside chat during the conference on September 4 at 3:00 p.m. ET, showcasing the company's proactive approach to investor relations [1]. - A live webcast of the presentation will be available on the Investor Relations section of the Integer website, ensuring accessibility for interested parties [2].